Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Exploring CK0804 add-on therapy for myelofibrosis patients with suboptimal ruxolitinib response.
Nuvisertib shows durable clinical efficacy for patients with R/R myelofibrosis.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Exploring CK0804 add-on therapy for myelofibrosis patients with suboptimal ruxolitinib response.
Nuvisertib shows durable clinical efficacy for patients with R/R myelofibrosis.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
